7-Chloro-8-Methylquinoline | CAS:78941-93-2

We serve 7-Chloro-8-Methylquinoline CAS:78941-93-2 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
7-Chloro-8-Methylquinoline

CAS No: 78941-93-2
Product Name: 7-Chloro-8-Methylquinoline
Other Name:
7-Chloro-8-Methylquinoline
 
Density: 1.2±0.1 g/cm3
Boiling Point: 278.0±0.0 °C at 760 mmHg
Molecular Formula: C10H8ClN
Molecular Weight: 177.630
Flash Point: 157.5±7.4 °C
Exact Mass: 177.034531
PSA: 12.89000
LogP: 3.30
Vapour Pressure: 0.0±0.5 mmHg at 25°C
Index of Refraction: 1.635
 
Specification
Appearance: White to beige solid
Assay: ≥99.0%
Loss on drying: ≤0.5%
 
Application
Intermediates of Quinclorac CAS: 84087-01-4.
Be used as pesticide intermediate, mainly used in the synthesis of the herbicide Quinclorac.
 
Package: 25kg/drum, can also be designed according to customer requirements.
Storage: Store in cool place. Keep container tightly closed in a dry and well-ventilated place.



Contact us for information like 7-Chloro-8-Methylquinoline chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,7-Chloro-8-Methylquinoline physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,7-Chloro-8-Methylquinoline Use and application,7-Chloro-8-Methylquinoline technical grade,usp/ep/jp grade.


Related News: This is called API. A small amount of the active ingredient has an effect, so only a tiny part of the active ingredient is contained in medicine.2,3,4-Trimethoxybenzaldehyde manufacturer This is called API. A small amount of the active ingredient has an effect, so only a tiny part of the active ingredient is contained in medicine.1-Naphthyl acetonitrile supplier Professionally produce and submit DMF files, and supplement data at any time during the patent challenge of formulation companies.N-(2-Nitrophenyl)-3-oxobutanamide vendor Green Valley said it would launch the drug “very soon” in China. The company also aims to roll out a phase-3 clinical trial with sites in the United States, Europe and Asia in early 2020 to facilitate global regulatory approval of the drug.Green Valley said it would launch the drug “very soon” in China. The company also aims to roll out a phase-3 clinical trial with sites in the United States, Europe and Asia in early 2020 to facilitate global regulatory approval of the drug.